Literature DB >> 20380491

Candidate selection for prostate cancer focal therapy.

Samir S Taneja1, Malcolm Mason.   

Abstract

Focal therapy has emerged as a potential treatment paradigm for men with localized prostate cancer, because it serves as a medium between the ambiguity of surveillance and the potential reduction of quality of life observed with radical treatment. Candidate selection remains the major challenge of implementing focal therapy in clinical practice. While focal therapy is potentially widely applicable, there is general consensus that initial efforts to initiate focal therapy protocols in practice should be limited to men with disease features that are low to low-intermediate risk, thereby limiting the likelihood of early systemic failure. Selection of candidates is first dependent on the intent of focal therapy. Curative intent focal therapy is limited to a small number of men with isolated, low-risk, unifocal, or unilateral disease. In men for whom local control-and potential prolongation of the natural history of disease-is desired, mapping strategies would focus on identification of the dominant site of disease and ruling out high-risk features. Tools such as conventional transrectal biopsy, transperineal saturation biopsy, and prostate MRI all have relative merits and shortcomings. While ultimately limitation of biopsy is desirable through combinations of transrectal biopsy and imaging, for now, limitations of conventional imaging modalities make it likely that most men will need transperineal saturation biopsy before inclusion in focal therapy protocols.

Entities:  

Mesh:

Year:  2010        PMID: 20380491     DOI: 10.1089/end.2010.0006

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  8 in total

Review 1.  Image guidance in the focal treatment of prostate cancer.

Authors:  Anthony N Hoang; Dmitry Volkin; Nitin K Yerram; Srinivas Vourganti; Jeffrey Nix; W Marston Linehan; Bradford Wood; Peter A Pinto
Journal:  Curr Opin Urol       Date:  2012-07       Impact factor: 2.309

2.  Imaging of prostate cancer: a platform for 3D co-registration of in-vivo MRI ex-vivo MRI and pathology.

Authors:  Clement Orczyk; Artem Mikheev; Andrew B Rosenkrantz; Jonathan Melamed; Samir S Taneja; Henry Rusinek
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2012-02-23

3.  Prostate cancer. Saturation biopsy does not accurately localize tumors.

Authors:  Oliver Sartor
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

4.  Focal therapy for prostate cancer - where are we in 2011?

Authors:  Michael S Borofsky; Timothy Ito; Andrew B Rosenkrantz; Samir S Taneja
Journal:  Ther Adv Urol       Date:  2011-08

Review 5.  Prostate focused ultrasound focal therapy--imaging for the future.

Authors:  Olivier Rouvière; Albert Gelet; Sébastien Crouzet; Jean-Yves Chapelon
Journal:  Nat Rev Clin Oncol       Date:  2012-08-21       Impact factor: 66.675

Review 6.  Focal therapy for prostate cancer: The current status.

Authors:  Susan Marshall; Samir Taneja
Journal:  Prostate Int       Date:  2015-03-23

7.  Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.

Authors:  Samir S Taneja; James Bennett; Jonathan Coleman; Robert Grubb; Gerald Andriole; Robert E Reiter; Leonard Marks; Abdel-Rahmene Azzouzi; Mark Emberton
Journal:  J Urol       Date:  2016-06-09       Impact factor: 7.450

8.  Primary Zonal High Intensity Focused Ultrasound for Prostate Cancer: Results of a Prospective Phase IIa Feasibility Study.

Authors:  Roland Van Velthoven; Fouad Aoun; Ksenija Limani; Krishna Narahari; Marc Lemort; Alexandre Peltier
Journal:  Prostate Cancer       Date:  2014-01-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.